Mesenchymal stromal cells application for experimental genital tuberculosis combination therapy

Abstract

BACKGROUND: Cell therapy is a promising trend in treating characterized by inflammation and sclerosis diseases such as genital tuberculosis, marked by pelvic inflammatory disease and uterine tube occlusion.

AIM: Efficacy evaluation of combined mesenchymal stem cells and specific polychemotherapy treatment of the experimental genital tuberculosis.

MATERIALS AND METHODS: Chinchilla rabbits (n = 27) were divided on 4 groups. Group 1 (n = 6) comprised control group, healthy animals. Group 2 (n = 7) infected with genital tuberculosis, without treatment. Group 3 (n = 7) infected with genital tuberculosis, treated with anti-tuberculous drugs only. Group 4 (n = 7) infected with genital tuberculosis, treated with anti-tuberculous drugs and mesenchymal stem cells. Culture of M. tuberculosis Erdman in dose 10⁷ CFU/0.2 ml was injected under the left uterine tube serosa for the genital tuberculosis modelling. For treatment efficacy evaluation following tests were used: full blood count, blood chemistry, hysterosalpingography, diagnostic laparoscopy, peritoneal macrophage phagocytic activity assessment.

RESULTS: Infected with genital tuberculosis animals had leukocytosis, elevated C-reactive protein, swelled and occluded uterine tubes. Treated with anti-tuberculous drugs and mesenchymal stem cells rabbits had lower white blood cell count (8.18 ± 1.39 · 10⁹/L vs 9.32 ± 1.36 · 10⁹/L, р < 0.05) and C-reactive protein (1.1 ± 0.8 mg/L vs 2.2 ± 1.2 mg/L, р < 0.01) compared to animal treated with anti-tuberculous drugs only. Animals in group 4 had also increased peritoneal macrophage phagocytic activity. Treated with mesenchymal stem cells animals had unobstructed uterine tubes, stabilized adhesive process within small pelvis with reparative process prevalence.

CONCLUSIONS: Mesenchymal stem cells combined with anti-tuberculous drugs therapy favors reparative process in uterine tubes in genital tuberculosis.

Keywords

stem cells / tuberculosis / mesenchymal stromal cells / genital tuberculosis / salpingitis / infertility

References

[1] Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708. DOI: 10.1093/humupd/dmw025

[2] Balen A.H., Morley L.C., Misso M. et al. The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance // Hum. Reprod. Update. 2016. Vol. 22. No. 6. P. 687–708. DOI: 10.1093/humupd/dmw025

[3] Trohatou O, Roubelakis MG. Mesenchymal Stem/Stromal Cells in regenerative medicine: Past, present, and future. Cell Reprogram. 2017;19(4):217–224. DOI: 10.1089/cell.2016.0062

[4] Trohatou O., Roubelakis M.G. Mesenchymal Stem/Stromal Cells in regenerative medicine: Past, present, and future // Cell Reprogram. 2017. Vol. 19. No. 4. P. 217–224. DOI: 10.1089/cell.2016.0062

[5] Djuwantono T, Permadi W, Septiani L, et al. Female genital tuberculosis and infertility: serial cases report in Bandung, Indonesia and literature review. BMC Res Notes. 2017;10(1):683. DOI: 10.1186/s13104-017-3057-z

[6] Djuwantono T., Permadi W., Septiani L. et al. Female genital tuberculosis and infertility: serial cases report in Bandung, Indonesia and literature review // BMC Res Notes. 2017. Vol. 10. No. 1. P. 683. DOI: 10.1186/s13104-017-3057-z

[7] Sharma JB. Current diagnosis and management of female genital tuberculosis. J Obstet Gynaecol India. 2015;65(6):362–371. DOI: 10.1007/s13224-015-0780-z

[8] Sharma J.B. Current diagnosis and management of female genital tuberculosis // J. Obstet. Gynaecol. India. 2015. Vol. 65. No. 6. P. 362–371. DOI: 10.1007/s13224-015-0780-z

[9] World Health Organization. [Internet]. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. [cited 2021 Nov 23]. Available from: https://reliefweb.int/sites/reliefweb.int/files/resources/9789241565516-eng.pdf

[10] World Health Organization. [Internet]. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. [дата обращения 23.11.2021]. Доступ по ссылке: https://reliefweb.int/sites/reliefweb.int/files/resources/9789241565516-eng.pdf

[11] Das M, Sundell IB, Koka PS. Adult mesenchymal stem cells and their potency in the cell-based therapy. J Stem Cells. 2013;8(1):1–16.

[12] Das M., Sundell I.B., Koka P.S. Adult mesenchymal stem cells and their potency in the cell-based therapy // J. Stem. Cells. 2013. Vol. 8. No. 1. P. 1–16.

[13] Jin HJ, Bae YK, Kim M, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013;14(9):17986–18001. DOI: 10.3390/ijms140917986

[14] Jin H.J., Bae Y.K., Kim M. et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy // Int. J. Mol. Sci. 2013. Vol. 14. No. 9. P. 17986–18001. DOI: 10.3390/ijms140917986

[15] Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016;28(3):217–222. DOI: 10.1097/gco.0000000000000268

[16] Kawamura K., Kawamura N., Hsueh A.J. Activation of dormant follicles: a new treatment for premature ovarian failure? // Curr. Opin. Obstet. Gynecol. 2016. Vol. 28. No. 3. P. 217–222. DOI: 10.1097/gco.0000000000000268

[17] Veryasov VN, Vartanyan EV. New cell technologies for recovery of the endometrium (scientific review). Vestnik ural’skoj medicinskoj akademicheskoj nauki. 2014;4(50):9–13. (In Russ.)

[18] Верясов В.Н., Вартанян Э.В. Новые клеточные технологии восстановления эндометрия (научный обзор) // Вестник Уральской медицинской академической науки. 2014. Т. 4. № 50. С. 9–14.

[19] Santamaria X, Cabanillas S, Cervelló I, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod. 2016;31(5):1087–1096. DOI: 10.1093/humrep/dew042

[20] Santamaria X., Cabanillas S., Cervelló I. et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study // Hum. Reprod. 2016. Vol. 31. No. 5. P. 1087–1096. DOI: 10.1093/humrep/dew042

[21] Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res Ther. 2019;10(1):46. DOI: 10.1186/s13287-019-1136-x

[22] Ling L., Feng X., Wei T. et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism // Stem. Cell Res. Ther. 2019. Vol. 10. No. 1. P. 46. DOI: 10.1186/s13287-019-1136-x

[23] Shvarts YaSh, Belogorodtsev SN, Filimonov PN. Transplantation of autologous mesenchymal stem cells in the experimental mycobacterial infection: impact of conditioning. Tuberkulez i bolezni legkih. 2015;12:31–36. (In Russ.)

[24] Шварц Я.Ш., Белогородцев С.Н., Филимонов П.Н. и др. Трансплантация аутологичных мезенхимальных стволовых клеток при экспериментальной микобактериальной инфекции: влияние условий кондиционирования // Туберкулез и болезни легких. 2015. № 12. С. 31–36.

[25] Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med. 2014;2(2):108–122. DOI: 10.1016/s2213-2600(13)70234-0

[26] Skrahin A., Ahmed R.K., Ferrara G. et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial // Lancet Respir. Med. 2014. Vol. 2. No. 2. P. 108–122. DOI: 10.1016/s2213-2600(13)70234-0

[27] Álvarez D, Levine M, Rojas M. Regenerative medicine in the treatment of idiopathic pulmonary fibrosis: current position. Stem Cells Cloning. 2015;8:61–65. DOI: 10.2147/sccaa.s49801

[28] Álvarez D., Levine M., Rojas M. Regenerative medicine in the treatment of idiopathic pulmonary fibrosis: current position // Stem. Cells Cloning. 2015. Vol. 8. P. 61–65. DOI: 10.2147/sccaa.s49801

[29] Patent RF na izobretenie No. 2015111979/01.04.2015. Byul. No. 29. Gusejnova FM, Niauri DA, Vinogradova TI, et al. Sposob modelirovaniya tuberkuleza zhenskikh polovykh organov. 2001 (In Russ.). [cited 2021 Nov 23]. Available from: http://www.nap.edu/books/0309074029/html/https://patentimages.storage.googleapis.com/aa/86/c9/f52af323b07018/RU2015111979A.pdf

[30] Патент РФ на изобретение № 2015111979 / 01.04.2015. Бюл. № 29. Гусейнова Ф.М., Ниаури Д.А., Виноградова Т.И. и др. Способ моделирования туберкулеза женских половых органов. [дата обращения 23.11.2021]. Доступ по ссылке: https://patentimages.storage.googleapis.com/aa/86/c9/f52af323b07018/RU2015111979A.pdf

[31] Sakhenberg EI, Nikolaenko NS, Pinaev GN. Actin cytoskeleton organization and spreading of bone marrow stromal cells and cartilage cells during their combined and independent cultivation on different extracellular matrix proteins. Cell and Tissue Biology. 2015;9(1). (In Russ.). DOI: 10.1134/S1990519X15010083

[32] Сахенберг Е.И., Николаенко Н.С., Пинаев Г.П. Исследование распластывания и организации актинового цитоскелета стромальных клеток костного мозга и клеток хряща при их раздельном и совместном культивировании на разных белках внеклеточного матрикса // Цитология. 2014. Т. 56. № 10. С. 708–716. DOI: 10.1134/S1990519X15010083

[33] Gudleviciene Z, Kundrotas G, Liudkeviciene R, et al. Quick and effective method of bone marrow mesenchymal stem cell extraction. Open Med (Wars). 2014;10(1):44–49. DOI: 10.1515/med-2015-0008

[34] Gudleviciene Z., Kundrotas G., Liudkeviciene R. et al. Quick and effective method of bone marrow mesenchymal stem cell extraction // Open Med. (Wars). 2014. Vol. 10. No. 1. P. 44–49. DOI: 10.1515/med-2015-0008

[35] Albertine KH, Gee MH. In vivo labeling of neutrophils using a fluorescent cell linker. J Leukoc Biol. 1996;59(5):631–638. DOI: 10.1002/jlb.59.5.631

[36] Albertine K.H., Gee M.H. In vivo labeling of neutrophils using a fluorescent cell linker // J. Leukoc Biol. 1996. Vol. 59. No. 5. P. 631–638. DOI: 10.1002/jlb.59.5.631

[37] Strukov AI. Formy legochnogo tuberkuleza v morfologicheskom osveshсhenii. Ch 2. Biblioteka patologoanatoma: nauchno-prakticheskiy zhurnal im. N.N. Anichkova. 2014;152:86.

[38] Струков А.И. Формы легочного туберкулеза в морфологическом освещении. Ч. 2 // Библиотека патологоанатома: научно-практический журнал им. Н.Н. Аничкова. 2014. № 152.

[39] Khan A, Hunter RL, Jagannath C. Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity. Tuberculosis (Edinb). 2016;101S:S45–S52. DOI: 10.1016/j.tube.2016.09.019

[40] Khan A., Hunter R.L., Jagannath C. Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity // Tuberculosis (Edinb). 2016. Vol. 101S. P. S45–S52. DOI: 10.1016/j.tube.2016.09.019

[41] Hegyi B, Környei Z, Ferenczi S, et al. Regulation of mouse microglia activation and effector functions by bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2014;23(21):2600–2612. DOI: 10.1089/scd.2014.0088

[42] Hegyi B., Környei Z., Ferenczi S. et al. Regulation of mouse microglia activation and effector functions by bone marrow-derived mesenchymal stem cells // Stem. Cells Dev. 2014. Vol. 23. No. 21. P. 2600–2612. DOI: 10.1089/scd.2014.0088

[43] D’souza N, Rossignoli F, Golinelli G, et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015;13:186. DOI: 10.1186/s12916-015-0426-0

[44] D’souza N., Rossignoli F., Golinelli G. et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies // BMC Med. 2015. Vol. 13. P. 186. DOI: 10.1186/s12916-015-0426-0

[45] Joshi L, Chelluri LK, Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: A concise review. Arch Immunol Ther Exp (Warsz). 2015;63(6):427–433. DOI: 10.1007/s00005-015-0347-9

[46] Joshi L., Chelluri L.K., Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: A concise review // Arch. Immunol. Ther. Exp. (Warsz). 2015. Vol. 63. No. 6427–6433. DOI: 10.1007/s00005-015-0347-9

RIGHTS & PERMISSIONS

Eсо-Vector